After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, the much-anticipated T-Cell Test from Hyris, based on innovative qPCR technology, is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of the Hyris System™.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.

Hyris is going to present its new test to detect the body's T Cell immune response to SARS-CoV-2 on 17 December 2021, at "A-WISH", Alicante-Winter Immunology Symposium in Health, which will address strategies for the COVID-19 response and the development of the vaccines against SARS-CoV-2. This new solution leverages the Hyris System™, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Hyris developed a rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the power of the renowned HYRIS bCUBE™ and the whole Hyris SystemTM. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Hyris developed a rapid T-cell test to track patients' immunity levels to SARS-CoV-2 for global clinical use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the Hyris SystemTM, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

SpartaCovid Helps Business Establishments Welcome Their Employees Back to the Workforce

Companies Across the Nation Can Take the First Step on the Path to Economic Recovery

New AI Platform Accelerates Scientific Research and Drug Discovery, includes over 300 Million Product Listings from 50,000 Vendors

Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted an Australian Patent. The Trianni Mouse Platform provides the complete human antibody repertoire for the facile isolation of monoclonal antibodies.

The Labscoop application will allow Atlas Antibodies to highlight product quality, reliability and increase accessibility among US, European, and Canadian researchers.

JIR aims to serve the largest selection and highest quality of secondary reagents for scientists and research institutions all around the globe.

Innovative recombinant manufacturing processes by Absolute Antibody makes engineered antibodies a possibility for all researchers rather than a select few backed by big pharma.

Labscoop Welcomes Industry Leading Immunology Antibodies and Ancillary Reagents Manufacturer Tonbo Biosciences. One of the fastest growing life science companies offering high performance, value-oriented products of the highest quality.

OriGene announced today it has signed an agreement with One World Lab to become a global distributor of OriGene's antibody portfolio that includes premium branded UltraMAB® monoclonal antibodies, internally developed and validated through OriGene's protein high density chips for mono specificity, as well as TrueMAB® monoclonal antibodies that are generated with full length protein antigens.

Ebola detection kits for humans and animals are now possible using ADI antibody or antigen ELISA kits with results in less than 2 hours. Ebola Rapid test cards, similar to pregnancy tests, have also been developed that provide results in 2-10 mins.

For the first half of the fiscal year 2011, HyTest reported revenues of 5,4 million euros, which is an increase from the 4,7 million euros reported for the same period in 2010. Operating income was high 2,1 million euros - in the percents 39%.

AbboMax offers nine novel anti- histone H3 antibodies specific for a mono-, di-, or tri-methylated state of Lys4, Lys9, and Lys27.
Methylation is involved in regulation of gene expression, protein function and RNA metabolism

Novus Biologicals, a leading international supplier of high quality antibodies and proteins to the bioresearch industry, is pleased to announce the introduction of a new range of Beta Amyloid antibodies to their antibody catalogue.

Novus Biologicals, an international supplier of antibodies, announce that they are attending a variety of tradeshows across Europe this summer.

GeoVax is developing a vaccine that presents the natural form of HIV envelope proteins to the immune system on virus-like particles with the envelope proteins present in clusters of three, a confirmation known as trimers.

Izon Science unveils latest breakthrough in nanoparticle analysis at 2010 BIO International Convention in Chicago

Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, announce that they have launched the first TMEM97 antibody onto the market.

Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have launched a new HIF Prolyl Hydroxylase antibody for use in research.

Bio-Synthesis, Inc. provides custom products for researchers and pharmaceutical companies.

The new uses and benefits of anti-drug antibodies, examined by Bio-Synthesis, Inc.

Bio-Synthesis has teamed up with BioConference Live for a revolutionary event. BioConference Live is a free, online-only conference for the life sciences and laboratory science community.